In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
Phase 2 interim data evaluating the combination of pracinostat and azacitidine in patients with Myelodysplastic Syndrome presented at the 2018 American Society of Hematology Annual Meeting
Themis Bioscience plans to expand measles vector immunomodulation portfolio into oncology indications
The new additions give PanFAM-1, a prospective study pursuing early diagnosis in people with a high heredity risk of pancreatic cancer, a boost in the effort to validate Immunovia's IMMray PanCan-d test
DNA immunotherapy and checkpoint inhibitor combination lead to remission
Company completes validation of prostate cancer PDX model and forms alliance with Shanghai Model Organisms Center
MolecularMD validates Thermo Fisher assay that can help in trial stratification
October saw medical technology provider iCAD Inc. share clinical results for its new digital breast tomosynthesis cancer detection software
Research team publishes research on the anticancer effects of retinoic acid on cancer stem cells

Columbia Business School report examines how cancer drugs have impacted mortality for patients
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.